NASDAQ, ALXN - Alexion Pharm Inc
We are a biopharmaceutical company engaged in the discovery, development and
delivery of biologic therapeutic products aimed at treating patients with severe
and life-threatening disease states, including hematologic and neurologic
diseases, cancer and autoimmune disorders. We have one marketed product, Soliris
? (eculizumab), which is the first therapy approved for the treatment of
patients with paroxysmal nocturnal hemoglobinuria, or PNH.
Since our incorporation in January 1992 until April 2007, we have devoted most
of our resources to drug discovery, research, and product and clinical
development. In March 2007, the Food and Drug Administration, or
2
--------------------------------------------------------------------------------
Table of Contents
FDA, granted marketing approval for Soliris. In the United States, Soliris is
indicated for the treatment of all patients with PNH to reduce hemolysis. ...
Read SEC Filing on NASDAQ.com »